Contrast enhancement at the time of progression of lower-grade IDH-mutant gliomas suggests transformation towards a higher grade of malignancy, which carries a different clinical significance compared to the presence of contrast enhancement at first diagnosis. This evidence concerns the gene IDH2 and glioma.